Product Description
Paclitaxel is a potent anticancer medication which can promote microtubule (MT) assembly, inhibit MT depolymerization, and change MT dynamics required for mitosis and cell proliferation.
IC50 & Target: IC50: 4 nM (MT)
In Vitro: Paclitaxel at 0.1, 0.5, and 1 μM reduces the proliferation and survival of CCRF-HSB-2 cells in a dose-dependent fashion and that the IC50 value of taxol is about 0.25 μM. Paclitaxel directly associates with the endoplasmic reticulum to stimulate the release of calcium into the cytosol, contributing to the induction of apoptosis.
In Vivo: In a SCID mouse xenograft model, low dose metronomic Paclitaxel treatment decreases lung dissemination of EGI-1 cells without significantly affecting their local tumor growth. Low doses of paclitaxel promot liver metastasis in mouse xenografts, which correlats with changes in estrogen metabolism in the host liver. Paclitaxel (2 mg/kg per treatment, black circles) induces mechanical hypersensitivity in the glabrous skin of the hindpaw.
Information
CAS No33069-62-4
FormulaC47H51NO14
PathwayCell Cycle/DNA Damage
Cytoskeleton
Antibody-drug Conjugate/ADC Related
TargetMicrotubule/Tubulin
Microtubule/Tubulin
ADC Cytotoxin
Specifications
FormWhite to off-white (Solid)
Purity / Grade99.49%
SolubilityDMSO : 500 mg/mL (585.5 mM)
H2O : < 0.1 mg/mL (insoluble)
Misc Information
Storage InstructionPowder: 4℃ for 3 years protect from light
In Solvent -80℃ for 6 Months; -20℃ for 1 month (protect from light)
Alternative NamesTaxol ; Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-
6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-
dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H cyclodeca[3,4]benz[1,2-b]oxet-9-ylester, (αR,βS)-
Observed Molecular Weight853.91